Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine from the University of Oxford and AstraZeneca uses a chimpanzee adenovirus vector.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
A recent study found that 42% of patients depleted 100 percent of their assets—an average loss of $92,000—within two years of diagnosis.
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Study shows eight-month survival advantage for those not previously treated with chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.